The efficacy arm of this investigation utilized a HER2-positive SKBR-3 breast cancer xenograft model in athymic nude mice to evaluate the therapeutic impact of dual-loaded nanoformulation (NTB+DTX−NP) and targeted trastuzumab-conjugated nanoparticles (TRZ−NP) compared to vehicle control (PBS). This evidence concerns the gene ERBB2 and breast cancer.